Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana
Shots:
- The Louisiana Department of Health signs a 5 years agreement with Asegua to implement the innovative payment model for the treatment of Hepatitis C and to improve the health of Louisiana citizens
- The innovative payment model allows the state of Louisiana to get an unlimited amount of Asegua’s authorized generic of Epclusa (sofosbuvir/velpatasvir) to treat patients within Louisiana’s Medicaid and Department of Corrections populations and caps the State’s medication costs
- Epclusa is a fixed-dose combination therapy indicated for the treatment of Hepatitis C genotype 1- 2- 3- 4- 5- or 6 infections with or without cirrhosis
Click here to read full press release/ article | Ref: Gilead | Image: Kratom Sciences
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com